# A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05913089/  
OnCo record `nct05913089` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TQB2450, Anlotinib in non-small-cell lung cancer and small-cell lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05913089 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 58 participants planned, started 2023-06-14 and due to reach its primary completion in 2026-06. Interventions recorded: TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05913089
- Phase: 2
- Setting: A Phase II/III Clinical Study on the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Perioperative Treatment of Resectable Stage II/III Non Small Cell Lung Cancer.
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT05913089: https://clinicaltrials.gov/study/NCT05913089

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [TQB2450](https://onco.cc/drugs/tqb2450/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct05913089.json